On December 20, 2022 the Ontario Ministry of Health announced that effective March 31, 2023, a transition policy will be implemented to expand the use of biosimilar medicines within the public drug program.

Ontario is one of the last provinces to implement a switch policy, and the decision will save over a hundred million dollars annually to the healthcare system.

The full government press release is available here: https://news.ontario.ca/en/release/1002611/ontario-expanding-safe-use-of-biosimilars

The ORA has been public with its position on biosimilar switching for many years now. To view our official position statement, please visit this link: https://ontariorheum.ca/wp-content/uploads/2022-ORA-Position-Statement-Biosimilar-Switching.pdf